课题基金 / 基金详情

Chemoenzymatic studies of aminoglycoside-resistance enzymes towards new drugs

Chemoenzymatic studies of aminoglycoside-resistance enzymes towards new drugs
新药氨基糖苷类耐药酶的化学酶学研究
批准号:
8185756
负责人:
Sylvie Garneau-Tsodikova
金额:
$45.77万
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-08-01 至 2015-07-31

项目摘要

项目成果

Sylvie Garneau-Tsodikova的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Aminoglycosides are broad-spectrum antibiotics used for treatment of serious bacterial infections, including the deadly tuberculosis and those accompanying AIDS, cystic fibrosis, and cancer. The emergence of pathogens resistant to these drugs represents a major threat to public health and underscores the need for new antimicrobial agents. In Aim 1, we propose to utilize aminoglycoside-modifying enzymes of the aminoglycoside acetyltransferase (AAC) family in conjunction with a newly developed 6'-N-acylation protecting group-free chemical methodology (i) to generate in vitro libraries of new and more potent N-acylated aminoglycoside antibiotics, and (ii) to develop aminoglycoside probes that will serve as baits for identification of novel therapeutic protein targets/pathways for these antibiotics. Our chemoenzymatic and chemical strategies offer an effective solution to the following problems: (i) there are no existing general synthetic methodologies for the creation of N-acylated aminoglycosides, and (ii) there are no efficient methods to chemically modify specific amine groups on an aminoglycoside that contains a series of chemically identical amines. A few existing examples that use solely chemical syntheses are too demanding on research time and cost and are limited to very specific cases. In Aim 2, we propose biochemical and structural studies of the mechanism of action and inhibition of a major determinant of aminoglycoside resistance in extensively drug-resistant strains of M. tuberculosis (XDR-TB). We expect this work to (i) advance the basic understanding of AG resistance of a variety of pathogenic bacteria, including M. tuberculosis, and (ii) provide a potential solution to overcome the aminoglycoside resistance problem in majority of XDR- TB. Relevance to public health: We expect that this work will contribute to the development of novel antibiotics with a potential to combat existing and newly emerging drug-resistant bacteria. PUBLIC HEALTH RELEVANCE: The proposed research is relevant to public health as an improved understanding of aminoglycoside- resistance enzymes is expected to lead to the discovery and development of new drugs and also in identifying drug targets. This research will enable us to better handle the problem of resistance of infectious bacteria to aminoglycoside antibiotics. The proposed research will have a major impact in two ways: (1) our novel chemical and chemoenzymatic methodologies for the rapid and facile regio- selective N-acylation of aminoglycosides will greatly reduce the cost and effort generally associated with such modifications, and (2) our study of the mechanism of action and inhibition of the major determinant of aminoglycosdie resistance in extensively drug-resistant M. tuberculosis will advance our understanding of drug resistance and also set a new paradigm of aminoglycoside acetyltransferase in the antibiotics field.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemoenzymatic studies of aminoglycoside-resistance enzymes towards new drugs
  • 批准号:
    8505365
  • 项目类别:
  • 资助金额:
    $40.36万
  • 财政年份:
    2011
  • 负责人:
    Sylvie Garneau-Tsodikova
  • 依托单位:
Novel aminoglycoside adjuvants and stand-alone agents to combat tuberculosis
  • 批准号:
    9403837
  • 项目类别:
  • 资助金额:
    $53.6万
  • 财政年份:
    2011
  • 负责人:
    Sylvie Garneau-Tsodikova
  • 依托单位:
Chemoenzymatic studies of aminoglycoside-resistance enzymes towards new drugs
  • 批准号:
    8307324
  • 项目类别:
  • 资助金额:
    $31.58万
  • 财政年份:
    2011
  • 负责人:
    Sylvie Garneau-Tsodikova
  • 依托单位:
Novel aminoglycoside adjuvants and stand-alone agents to combat tuberculosis
  • 批准号:
    10188396
  • 项目类别:
  • 资助金额:
    $54.8万
  • 财政年份:
    2011
  • 负责人:
    Sylvie Garneau-Tsodikova
  • 依托单位:
海外基金